Cargando…
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes toward cancer cells by bispecific antibodi...
Autores principales: | Satta, Alessandro, Grazia, Giulia, Caroli, Francesco, Frigerio, Barbara, Di Nicola, Massimo, Raspagliesi, Francesco, Mezzanzanica, Delia, Zaffaroni, Nadia, Gianni, Alessandro Massimo, Anichini, Andrea, Figini, Mariangela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823250/ https://www.ncbi.nlm.nih.gov/pubmed/31708930 http://dx.doi.org/10.3389/fimmu.2019.02514 |
Ejemplares similares
-
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020) -
Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
por: Rizzo, Andrea, et al.
Publicado: (2021) -
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging
por: Frigerio, Barbara, et al.
Publicado: (2016) -
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling
por: Roggiani, Francesca, et al.
Publicado: (2019) -
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)